{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:27:08Z","timestamp":1793827628431,"version":"4.6.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      This study was designed to investigate the detection rate and tumor uptake of\n                      <jats:sup>18<\/jats:sup>\n                      F-AlF-NOTA-De-FAPI PET\/CT in newly diagnosed high-risk prostate cancer (PCa), compared with\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      This study enrolled 48 patients with biopsy-diagnosed, treatment-naive high-risk PCa who underwent\n                      <jats:sup>18<\/jats:sup>\n                      F-AlF-NOTA-De-FAPI,\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11, and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT between April and December 2024. A head-to-head comparison of detection rate and tumor uptake was performed among the 3 tracers. In addition,\n                      <jats:sup>18<\/jats:sup>\n                      F-AlF-NOTA-De-FAPI and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 dual-tracer PET was used to characterize the imaging phenotypes of each lesion and interlesional heterogeneity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 477 lesions were detected by the 3 PET tracers.\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 exhibited the highest overall detection rate (96.4%), followed by\n                      <jats:sup>18<\/jats:sup>\n                      F-AlF-NOTA-De-FAPI (81.1%) and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG (66.0%). A total of 17\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11-negative lesions were identified in 8 patients, all of which were detected by\n                      <jats:sup>18<\/jats:sup>\n                      F-AlF-NOTA-De-FAPI, whereas only 12 were detected by\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG. Combined\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 and\n                      <jats:sup>18<\/jats:sup>\n                      F-AlF-NOTA-De-FAPI PET identified all lesions detected by triple-tracer PET. Based on relative tracer dominance of dual-tracer PET, patients were classified as PSMA-dominant (n=23), FAPI-dominant (n=5), or mixed phenotype (n=20). The mixed phenotype with marked interlesional heterogeneity might be associated with more advanced clinical characteristics, with a higher proportion of metastatic disease and a greater metastatic burden.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>18<\/jats:sup>\n                      F-AlF-NOTA-De-FAPI is a promising PET tracer for newly diagnosed high-risk PCa. It may improve the detection rate of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11-negative lesions and provide complementary information that could reflect interlesional heterogeneity. The clinical value of combining\n                      <jats:sup>18<\/jats:sup>\n                      F-AlF-NOTA-De-FAPI and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET requires further validation in larger prospective cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006690","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T17:02:55Z","timestamp":1792774975000},"page":"1067-1077","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A Head-to-Head Comparison of Detection Rate and Tumor Uptake of FAPI, PSMA, and FDG PET\/CT in Newly Diagnosed High-risk Prostate Cancer"],"prefix":"10.1097","volume":"51","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhao","family":"Dong","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Xu","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penghui","family":"Liao","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxing","family":"Du","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6503-7750","authenticated-orcid":false,"given":"Cong","family":"Hu","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0495-1834","authenticated-orcid":false,"given":"Zehong","family":"Peng","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihan","family":"Lai","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Zheng","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahua","family":"Pan","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinjie","family":"Zhu","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Liu","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohua","family":"Chen","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Dong","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xue","sequence":"additional","affiliation":[{"name":"Urology"},{"name":"Department of Urology, Nantong First People\u2019s Hospital, Nantong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"R1-20261104","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","article-title":"High-risk prostate cancer-classification and therapy","volume":"11","author":"Chang","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","article-title":"Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis","volume":"74","author":"Han","year":"2018","journal-title":"Eur Urol"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2967\/jnumed.120.245605","article-title":"68Ga-PSMA PET\/CT for primary lymph node and distant metastasis NM staging of high-risk prostate cancer","volume":"62","author":"Klingenberg","year":"2021","journal-title":"J Nucl Med"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s00259-013-2361-7","article-title":"Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET\/CT: Utility and limitations","volume":"40","author":"Jadvar","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40644-023-00599-y","article-title":"Meta-analysis of 18F-PSMA-1007 PET\/CT, 18F-FDG PET\/CT, and 68Ga-PSMA PET\/CT in diagnostic efficacy of prostate cancer","volume":"23","author":"Yu","year":"2023","journal-title":"Cancer Imaging"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat Rev Urol"},{"key":"R9-20261104","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","article-title":"Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer","volume":"76","author":"Paschalis","year":"2019","journal-title":"Eur Urol"},{"key":"R10-20261104","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s00259-025-07646-9","article-title":"Dual-tracer PET\/CT identifies an aggressive PSMA-negative\/FDG-positive phenotype predicting early failure of radical prostatectomy in treatment-naive prostate cancer","volume":"53","author":"Chen","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R11-20261104","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1007\/s00259-025-07588-2","article-title":"Beyond PSMA: the essential complementary role of MRI in staging prostate cancer with low-PSMA expression phenotypes","volume":"53","author":"Chen","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20261104","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1007\/s00259-025-07140-2","article-title":"CD13 as a potential theranostic target for prostate-specific membrane antigen-negative prostate cancer and first-in-human study of [18F]AlF-CD13-L1 PET\/CT imaging","volume":"52","author":"Tang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-20261104","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J Nucl Med"},{"key":"R14-20261104","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1470-2045(25)00299-2","article-title":"[68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial","volume":"26","author":"Pabst","year":"2025","journal-title":"Lancet Oncol"},{"key":"R15-20261104","first-page":"1952","article-title":"FAP and PSMA expression by immunohistochemistry and PET imaging in castration-resistant prostate cancer: a translational pilot study","volume":"65","author":"Huang","year":"2024","journal-title":"J Nucl Med"},{"key":"R16-20261104","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1097\/RLU.0000000000005064","article-title":"Contribution of 68Ga-DOTA-FAPI-04 PET\/CT to prostate cancer imaging: complementary role in PSMA-negative cases","volume":"49","author":"Erg\u00fcl","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R17-20261104","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1007\/s00259-025-07352-6","article-title":"Multitracer comparison of gold standard PSMA-PET\/CT with 68Ga-FAPI and 18F-FDG in high-risk prostate cancer: a proof-of-concept study","volume":"52","author":"Mahmoud","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R18-20261104","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: Joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R19-20261104","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R20-20261104","doi-asserted-by":"crossref","first-page":"108445","DOI":"10.1016\/j.bioorg.2025.108445","article-title":"Development and evaluation of 18F-labeled novel radiopharmaceuticals for PET imaging of fibroblast activation protein expressing tumors","volume":"160","author":"Zhang","year":"2025","journal-title":"Bioorg Chem"},{"key":"R21-20261104","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"R22-20261104","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00259-024-06891-8","article-title":"Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-\/[18F]F-PSMA-11\/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET\/CT: a pilot study","volume":"52","author":"Pabst","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R23-20261104","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1007\/s00259-025-07650-z","article-title":"Head-to-head comparison of 18F-FAP-2286 PET\/CT and 18F-FDG PET\/CT in the diagnosis and staging of clear cell renal cell carcinoma: a prospective study","volume":"53","author":"Cui","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R24-20261104","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"R25-20261104","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2967\/jnumed.121.262426","article-title":"Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: Interim analysis of a prospective translational exploratory study","volume":"63","author":"Mona","year":"2022","journal-title":"J Nucl Med"},{"key":"R26-20261104","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00259-021-05423-y","article-title":"High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics","volume":"49","author":"Kesch","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R27-20261104","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","article-title":"Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET\/CT in cancer patients","volume":"48","author":"Giesel","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R28-20261104","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2967\/jnumed.123.266652","article-title":"Diagnostic accuracy of 68Ga-FAPI versus 18F-FDG PET in patients with various malignancies","volume":"65","author":"Hirmas","year":"2024","journal-title":"J Nucl Med"},{"key":"R29-20261104","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1097\/RLU.0000000000004825","article-title":"Fibroblast activation protein-targeted PET\/CT imaging in a treatment-naive prostate cancer patient with low PSMA expression","volume":"48","author":"Mu","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R30-20261104","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/RLU.0000000000004349","article-title":"68Ga-FAPI PET\/CT detected non-PSMA\/FDG-avid primary tumor in de novo metastatic prostate cancer","volume":"47","author":"Pang","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R31-20261104","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","article-title":"Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer","volume":"4","author":"Bakht","year":"2023","journal-title":"Nat Cancer"},{"key":"R32-20261104","doi-asserted-by":"crossref","first-page":"13","DOI":"10.62347\/HVLF3619","article-title":"Molecular imaging reveals the heterogeneous progression of tumor cells and tumor stroma: a practice of FDG PET and FAPI PET in diagnosing PSMA-negative bone metastases of progressive prostate cancer","volume":"14","author":"Zhu","year":"2024","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"R33-20261104","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.2967\/jnumed.124.268020","article-title":"Intrapatient intermetastatic heterogeneity determined by triple-tracer PET imaging in mCRPC patients and correlation to survival: the 3TMPO cohort study","volume":"65","author":"Pouliot","year":"2024","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:00:24Z","timestamp":1793826024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006690","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"2026-05-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}